FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	OMB APPROVAL							
	OMB Number:	3235-0287						
	Estimated average burden							
- 1								

					Or	Section	n 30(n)	or the	investmer	it Cor	npany Act	01 1940	0							
Name and Address of Reporting Person*  VON RICKENBACH JOSEF H						2. Issuer Name <b>and</b> Ticker or Trading Symbol AILERON THERAPEUTICS INC [ ALRN ]								] (Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last)			(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/28/2024								<ul><li>X Director</li><li>Officer</li><li>below)</li></ul>	(give title		Other (s below)				
C/O AILERON THERAPEUTICS, INC 738 MAIN STREET #398				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
(Street) WALTHAM MA 02451																filed by Mo		orting Perso n One Repo		
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant t satisfy the affirmative defense conditions of Rule 10b5-1(c). See I							to a cont	ract, instructi on 10.	on or writter	n plan t	hat is intende	d to			
		Tab	le I - Nor	n-Deriv	ative	Sec	uritie	s Ac	quired,	Dis	posed o	of, or	Bene	eficial	ly Owned	t				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Day/Year)  2A. Deemed Execution I if any (Month/Day			Date	Code (							es ally Following	Form (D) o	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	t (A) or (D)		Price		action(s) .3 and 4)			(Instr. 4)		
		7	Table II -						uired, D s, optior						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 5) Erivativ. 8) Derivativ. 8 Securitie: Acquired Acquired		tive ties red sed	6. Date Exercisable and Expiration Date (Month/Day/Year)  (Month/Day/Year)  7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)				4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Ownership Form: Direct (D)	11. Natur of Indired Benefici Ownersh (Instr. 4)						
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	O N O	lumber						
Stock																				

## **Explanation of Responses:**

1. This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders.

(1)

2,725

## Remarks:

Option

(right to buy)

Exhibit 24.1 Power of Attorney

/s/ Brian Windsor, attorney-in-

2,725

\$0.00

2,725

D

03/01/2024 fact for Josef H. von

Rickenbach

Common Stock

02/27/2034

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/28/2024

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Brian Windsor, Ph.D., and Charles Garner, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

- 1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of Aileron Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");
- 2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;
- 3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and
- 4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of February 29th, 2024.							
	/s/ Josef H. Von Rickenbach Signature						
	Josef H. Von Rickenbach						
	Print Name						
[Signature Page to Limited Power of Attorney for Section 16.	Reporting Obligations]						